In the subgroup without diabetes, the pooled HR was 0.88 [95% CI 0.73–1.07, p = 0.12], not reaching statistical significance, Figure 4B. However, the consistency in direction of effect favoring SGLT2 inhibitors in both analyses suggests a potential benefit even in patients without diabetes. Here, SLC5A2 is linked to diabetes mellitus.